| October 27, 2025 | Yeztugo® (lenacapavir) | GILD | Primary completion | HIV-1-infection | Completed | ClinicalTrials.gov |
| September 29, 2025 | Yeztugo® (lenacapavir) | GILD | Primary completion | HIV-1-infection | Completed | ClinicalTrials.gov |
| August 7, 2025 | — | GILD | Earnings | — | Completed | SEC 8-K Exhibit 99.1 |
| July 30, 2025 | Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| July 4, 2025 | sacituzumab govitecan-hziy (IMMU-132) | GILD | Primary completion | Locally Advanced or Metastatic Unresectable Urothelial Cancer | Completed | ClinicalTrials.gov |
| 2H 2025Half-year disclosed | Yeztugo® (lenacapavir) | GILD | Trial start | — | Scheduled | SEC 8-K Exhibit 99.1 |
| June 20, 2025 | Descovy (emtricitabine; tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 20, 2025 | Tybost (cobicistat) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 19, 2025 | Yeztugo® (lenacapavir) | GILD | PDUFA date | — | Approved | SEC 8-K Exhibit 99.1 |
| June 18, 2025 | Yeztugo (lenacapavir; lenacapavir sodium) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |
| June 18, 2025 | Yeztugo® (lenacapavir) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |
| June 17, 2025 | fludarabine | GILD | Primary completion | Relapsed/Refractory Mantle Cell Lymphoma | Completed | ClinicalTrials.gov |
| June 13, 2025 | Tybost (cobicistat) | GILD | Primary completion | Acquired Immune Deficiency Syndrome (AIDS); HIV Infections | Completed | ClinicalTrials.gov |
| May 8, 2025 | obeldesivir (GS-5245) | GILD | Primary completion | RSV Infection | Withdrawn | ClinicalTrials.gov |
| April 24, 2025 | — | GILD | Earnings | — | Completed | SEC 8-K Exhibit 99.1 |
| April 24, 2025 | Yeztugo® (lenacapavir) | GILD | NDA/BLA accepted | — | Completed | SEC 8-K Exhibit 99.1 |
| February 19, 2025 | Odefsey (emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 11, 2025 | — | GILD | Earnings | — | Completed | SEC 8-K Exhibit 99.1 |
| November 25, 2024 | Yeztugo® (lenacapavir) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 14, 2024 | Livdelzi® (seladelpar) | GILD | FDA approval | To treat primary biliary cholangitis (PBC) | Approved | FDA Novel Drug Approvals |
| April 24, 2024 | Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| March 27, 2024 | Vemlidy (tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 28, 2024 | Veklury (remdesivir) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 23, 2024 | Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| July 13, 2023 | Veklury (remdesivir) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| December 22, 2022 | Yeztugo® (lenacapavir) | GILD | FDA approval | — | Approved | FDA Novel Drug Approvals |
| October 17, 2022 | Vemlidy (tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| October 14, 2022 | Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| Oct 2022Month disclosed | Hepcludex® (bulevirtide) | GILD | Complete Response Letter | with hepatitis delta virus infection | CRL issued | SEC Form 10-Q |
| April 27, 2022 | Epclusa (sofosbuvir; velpatasvir) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| April 25, 2022 | Veklury (remdesivir) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 28, 2022 | Yeztugo® (lenacapavir) | GILD | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| January 21, 2022 | Veklury (remdesivir) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 7, 2022 | Descovy (emtricitabine; tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 7, 2022 | Genvoya (cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| October 7, 2021 | Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 10, 2021 | Epclusa (sofosbuvir; velpatasvir) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 10, 2021 | Epclusa (sofosbuvir; velpatasvir) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |
| February 24, 2021 | Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 5, 2021 | Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| October 22, 2020 | Veklury (remdesivir) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |
| August 18, 2020 | Vemlidy (tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| July 14, 2020 | Epclusa (sofosbuvir; velpatasvir) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| March 19, 2020 | Epclusa (sofosbuvir; velpatasvir) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 4, 2020 | Vemlidy (tenofovir alafenamide fumarate) | GILD | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 28, 2019 | Sovaldi® (sofosbuvir) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |
| August 28, 2019 | Harvoni (ledipasvir; sofosbuvir) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |
| February 7, 2018 | Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |
| July 18, 2017 | Vosevi (sofosbuvir; velpatasvir; voxilaprevir) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |
| November 10, 2016 | Vemlidy (tenofovir alafenamide fumarate) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |
| June 28, 2016 | Epclusa (sofosbuvir; velpatasvir) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |
| April 4, 2016 | Descovy (emtricitabine; tenofovir alafenamide fumarate) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |
| March 1, 2016 | Odefsey (emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |